Reduction in new metastases in breast cancer with adjuvant clodronate treatment

New England Journal of Medicine

Volumn 339, Issue 6, 1998, Pages 357-363

  Diel, Ingo J ^a,c   Solomayer, Erich Franz ^a   Costa, Serban D ^b   Gollan, Christina ^a   Goerner, Ronald ^a   Wallwiener, Diethelm ^a   Kaufmann, Manfred ^b   Bastert, Gunther ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GOSERELIN; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURGERY; CLINICAL OBSERVATION; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLODRONIC ACID; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0032491037     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199808063390601     Document Type: Article

References (35)

1. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In: Brunner KW, Fleisch H, Senn H-J, eds. Bisphosphonates and tumor osteolysis. Vol. 116 of Recent results in cancer research. Berlin, Germany: Springer-Verlag, 1989:1-28.
2. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996;97:2692-6.
3. Averbuch SD. New bisphosphonates in the treatment of bone metastases. Cancer 1993;72:Suppl:3443-52.
4. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
5. O'Rourke N, McCloskey E, Houghton F, Huss H, Kanis JA. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol 1995;13:929-34.
6. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993;11:59-65.
7. Hall DG, Stoica G. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res 1994;9:221-30.
8. Krempien B. Experimental findings on the osteoprotective potential of bisphosphonates against bone metastases and tumor-induced osteopathy: a pleading for an early and preventive administration. In: Orr FW, Singh G, eds. Bone metastasis - mechanisms and pathophysiology. New York: Springer, 1996:221-45.
9. Kanis JA, Powles T, Paterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996;16:663-7.
10. Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol 1992;10:1534-9.
11. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison to nodal status. J Natl Cancer Inst 1996;88:1652-8.
12. Redding WH, Coombes RC, Monaghan P, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983;2:1271-4.
13. Mansi JL, Easton D, Berger U, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
14. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev 1985;12:251-70.
15. Idem. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
16. Theriault RL, Hortobagyi GN. Bone metastasis in breast cancer. Anticancer Drugs 1992;3:455-62.
17. Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgström GH. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987;8:Suppl 1:S53-S56.
18. Elomaa I, Blomqvist C, Porkka L, et al. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 1988;42:111-6.
19. Kanis JA, O'Rourke N, McCloskey EV. Consequences of neoplasia induced bone resorption and the use of clodronate. Int J Oncol 1994;5:713-31.
20. Mundy GR. Mechanisms of osteolytic bone destruction. Bone 1991; 12:Suppl 1:S1-S6.
21. Mundy GR, Martin TJ. Pathophysiology of skeletal complications of cancer. In: Mundy GR, Martin TJ, eds. Physiology and pharmacology of bone. Berlin, Germany: Springer-Verlag, 1993:641-71.
22. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone 1995;17:Suppl 2:S101-S105.
23. Nemoto R, Uchida K, Tsutsumi M, Koiso K, Satou S, Satou T. A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium. J Cancer Res Clin Oncol 1987;113: 539-43.
24. Krempien B, Manegold C. Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate CL2MBP. Cancer 1993;72:91-8.
25. Krempien B, Wingen F, Eichmann T, Müller M, Schmähl D. Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-1-hydroxypropane-1,1-bisphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256. Oncology 1988;45:416.
26. Wingen F, Eichmann T, Manegold C, Krempien B. Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J Cancer Res Clin Oncol 1986;111:35-41.
27. Kostenuik PJ, Orr FW, Suyama K, Singh G. Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res 1993;53:5452-7.
28. Sasaki A, Boyce BF, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in nude mice. Cancer Res 1995;55: 3551-7.
29. Mönkkönen J, Heath TD. The effects of liposome-encapsulated and free clodronate on the growth of macrophage-like cells in vitro: the role of calcium and iron. Calcif Tissue Int 1993;53:139-46.
30. Mönkkönen J, Taskinen M, Auriola SOK, Urtti A. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro. J Drug Target 1994;2:299-308.
31. Rogers MJ, Chilton KM, Coxon, FP, et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 1996;11:1482-91.
32. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Löwik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996;98:698-705.
33. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 1997;57:3890-4.
34. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997;99:2509-17.
35. Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996;16:116-31.